Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CARGO Therapeutics, Inc. ( (CRGX) ) has issued an update.
On June 18, 2025, CARGO Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s governance and financial oversight. Stockholders elected three Class II Directors, Abraham Bassan, Kapil Dhingra, and David Lubner, to serve until the 2028 Annual Meeting. Additionally, the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by the stockholders.
The most recent analyst rating on (CRGX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on CARGO Therapeutics, Inc. stock, see the CRGX Stock Forecast page.
Spark’s Take on CRGX Stock
According to Spark, TipRanks’ AI Analyst, CRGX is a Underperform.
CARGO Therapeutics faces significant challenges with no revenue and increasing losses. The company’s decision to reduce workforce and pipeline efforts reflects financial distress. Although the technical indicators show some short-term upward momentum, the longer-term outlook remains weak. The negative valuation metrics further highlight profitability concerns. The strategic focus on CAR T therapy and potential partnerships may provide future opportunities but require careful financial management.
To see Spark’s full report on CRGX stock, click here.
More about CARGO Therapeutics, Inc.
Average Trading Volume: 693,895
Technical Sentiment Signal: Sell
Current Market Cap: $200.6M
For a thorough assessment of CRGX stock, go to TipRanks’ Stock Analysis page.